可溶性环氧化物水解酶活性的增加与射血分数保留的心衰患者的死亡率呈正相关:来自代谢组学的证据

IF 3.7 Q2 GENETICS & HEREDITY Phenomics (Cham, Switzerland) Pub Date : 2022-10-27 eCollection Date: 2023-02-01 DOI:10.1007/s43657-022-00069-8
Liyuan Peng, Ziping Song, Chengcheng Zhao, Kudusi Abuduwufuer, Yanwen Wang, Zheng Wen, Li Ni, Chenze Li, Ying Yu, Yi Zhu, Hualiang Jiang, Jinshan Shen, Xiangrui Jiang, Chen Chen, Xu Zhang, Dao Wen Wang
{"title":"可溶性环氧化物水解酶活性的增加与射血分数保留的心衰患者的死亡率呈正相关:来自代谢组学的证据","authors":"Liyuan Peng, Ziping Song, Chengcheng Zhao, Kudusi Abuduwufuer, Yanwen Wang, Zheng Wen, Li Ni, Chenze Li, Ying Yu, Yi Zhu, Hualiang Jiang, Jinshan Shen, Xiangrui Jiang, Chen Chen, Xu Zhang, Dao Wen Wang","doi":"10.1007/s43657-022-00069-8","DOIUrl":null,"url":null,"abstract":"<p><p>Epoxyeicosatrienoic acids (EETs) have pleiotropic endogenous cardiovascular protective effects and can be hydrolyzed to the corresponding dihydroxyeicosatrienoic acids by soluble epoxide hydrolase (sEH). Heart failure with preserved ejection fraction (HFpEF) has shown an increased prevalence and worse prognosis over the decades. However, the role of sEH activity in HFpEF remains unclear. We enrolled 500 patients with HFpEF and 500 healthy controls between February 2010 and March 2016. Eight types of sEH-related eicosanoids were measured according to target metabolomics, and their correlation with clinical endpoints was also analyzed. The primary endpoint was cardiac mortality, and the secondary endpoint was a composite of cardiac events, including heart failure (HF) readmission, cardiogenic hospitalization, and all-cause mortality. Furthermore, the effect of sEH inhibitors on cardiac diastolic function in HFpEF was investigated in vivo and in vitro. Patients with HFpEF showed significantly enhanced EET degradation by the sEH enzyme compared with healthy controls. More importantly, sEH activity was positively correlated with cardiac mortality in patients with HFpEF, especially in older patients with arrhythmia. A consistent result was obtained in the multiple adjusted models. Decreased sEH activity by the sEH inhibitor showed a significant effective effect on the improvement of cardiac diastolic function by ameliorating lipid disorders in cardiomyocytes of HFpEF mouse model. This study demonstrated that increased sEH activity was associated with cardiac mortality in patients with HFpEF and suggested that sEH inhibition could be a promising therapeutic strategy to improve diastolic cardiac function. Clinical trial identifier: NCT03461107 (https://clinicaltrials.gov).</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s43657-022-00069-8.</p>","PeriodicalId":74435,"journal":{"name":"Phenomics (Cham, Switzerland)","volume":"3 1","pages":"34-49"},"PeriodicalIF":3.7000,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883375/pdf/","citationCount":"0","resultStr":"{\"title\":\"Increased Soluble Epoxide Hydrolase Activity Positively Correlates with Mortality in Heart Failure Patients with Preserved Ejection Fraction: Evidence from Metabolomics.\",\"authors\":\"Liyuan Peng, Ziping Song, Chengcheng Zhao, Kudusi Abuduwufuer, Yanwen Wang, Zheng Wen, Li Ni, Chenze Li, Ying Yu, Yi Zhu, Hualiang Jiang, Jinshan Shen, Xiangrui Jiang, Chen Chen, Xu Zhang, Dao Wen Wang\",\"doi\":\"10.1007/s43657-022-00069-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Epoxyeicosatrienoic acids (EETs) have pleiotropic endogenous cardiovascular protective effects and can be hydrolyzed to the corresponding dihydroxyeicosatrienoic acids by soluble epoxide hydrolase (sEH). Heart failure with preserved ejection fraction (HFpEF) has shown an increased prevalence and worse prognosis over the decades. However, the role of sEH activity in HFpEF remains unclear. We enrolled 500 patients with HFpEF and 500 healthy controls between February 2010 and March 2016. Eight types of sEH-related eicosanoids were measured according to target metabolomics, and their correlation with clinical endpoints was also analyzed. The primary endpoint was cardiac mortality, and the secondary endpoint was a composite of cardiac events, including heart failure (HF) readmission, cardiogenic hospitalization, and all-cause mortality. Furthermore, the effect of sEH inhibitors on cardiac diastolic function in HFpEF was investigated in vivo and in vitro. Patients with HFpEF showed significantly enhanced EET degradation by the sEH enzyme compared with healthy controls. More importantly, sEH activity was positively correlated with cardiac mortality in patients with HFpEF, especially in older patients with arrhythmia. A consistent result was obtained in the multiple adjusted models. Decreased sEH activity by the sEH inhibitor showed a significant effective effect on the improvement of cardiac diastolic function by ameliorating lipid disorders in cardiomyocytes of HFpEF mouse model. This study demonstrated that increased sEH activity was associated with cardiac mortality in patients with HFpEF and suggested that sEH inhibition could be a promising therapeutic strategy to improve diastolic cardiac function. Clinical trial identifier: NCT03461107 (https://clinicaltrials.gov).</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s43657-022-00069-8.</p>\",\"PeriodicalId\":74435,\"journal\":{\"name\":\"Phenomics (Cham, Switzerland)\",\"volume\":\"3 1\",\"pages\":\"34-49\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2022-10-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883375/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Phenomics (Cham, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s43657-022-00069-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/2/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phenomics (Cham, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s43657-022-00069-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

摘要

环氧二十碳三烯酸(EETs)具有多种内源性心血管保护作用,可通过可溶性环氧化物水解酶(sEH)水解为相应的二羟基二十碳三烯酸。几十年来,射血分数保留型心力衰竭(HFpEF)的发病率越来越高,预后越来越差。然而,sEH 活性在 HFpEF 中的作用仍不清楚。我们在 2010 年 2 月至 2016 年 3 月间招募了 500 名 HFpEF 患者和 500 名健康对照者。根据目标代谢组学测量了八种与sEH相关的二十酸,并分析了它们与临床终点的相关性。主要终点是心脏死亡率,次要终点是心脏事件的综合指数,包括心衰(HF)再入院、心源性住院和全因死亡率。此外,还在体内和体外研究了sEH抑制剂对HFpEF患者心脏舒张功能的影响。与健康对照组相比,HFpEF 患者通过 sEH 酶降解 EET 的能力明显增强。更重要的是,sEH 活性与 HFpEF 患者的心脏死亡率呈正相关,尤其是在有心律失常的老年患者中。多重调整模型也得出了一致的结果。使用 sEH 抑制剂降低 sEH 活性对改善 HFpEF 小鼠模型心肌细胞脂质紊乱,从而改善心脏舒张功能有显著效果。这项研究表明,sEH活性的升高与HFpEF患者的心脏死亡率有关,并提示sEH抑制剂可能是改善心脏舒张功能的一种有前途的治疗策略。临床试验标识符:NCT03461107 (https://clinicaltrials.gov)。补充信息:在线版本包含补充材料,可在 10.1007/s43657-022-00069-8上查阅。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Increased Soluble Epoxide Hydrolase Activity Positively Correlates with Mortality in Heart Failure Patients with Preserved Ejection Fraction: Evidence from Metabolomics.

Epoxyeicosatrienoic acids (EETs) have pleiotropic endogenous cardiovascular protective effects and can be hydrolyzed to the corresponding dihydroxyeicosatrienoic acids by soluble epoxide hydrolase (sEH). Heart failure with preserved ejection fraction (HFpEF) has shown an increased prevalence and worse prognosis over the decades. However, the role of sEH activity in HFpEF remains unclear. We enrolled 500 patients with HFpEF and 500 healthy controls between February 2010 and March 2016. Eight types of sEH-related eicosanoids were measured according to target metabolomics, and their correlation with clinical endpoints was also analyzed. The primary endpoint was cardiac mortality, and the secondary endpoint was a composite of cardiac events, including heart failure (HF) readmission, cardiogenic hospitalization, and all-cause mortality. Furthermore, the effect of sEH inhibitors on cardiac diastolic function in HFpEF was investigated in vivo and in vitro. Patients with HFpEF showed significantly enhanced EET degradation by the sEH enzyme compared with healthy controls. More importantly, sEH activity was positively correlated with cardiac mortality in patients with HFpEF, especially in older patients with arrhythmia. A consistent result was obtained in the multiple adjusted models. Decreased sEH activity by the sEH inhibitor showed a significant effective effect on the improvement of cardiac diastolic function by ameliorating lipid disorders in cardiomyocytes of HFpEF mouse model. This study demonstrated that increased sEH activity was associated with cardiac mortality in patients with HFpEF and suggested that sEH inhibition could be a promising therapeutic strategy to improve diastolic cardiac function. Clinical trial identifier: NCT03461107 (https://clinicaltrials.gov).

Supplementary information: The online version contains supplementary material available at 10.1007/s43657-022-00069-8.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Investigation on Phenomics of Traditional Chinese Medicine from the Diabetes. Expert Consensus on Big Data Collection of Skin and Appendage Disease Phenotypes in Chinese. Synergistically Augmenting Cancer Immunotherapy by Physical Manipulation of Pyroptosis Induction. Report on the 4th Board Meeting of the International Human Phenome Consortium. A Noninvasive Approach to Evaluate Tumor Immune Microenvironment and Predict Outcomes in Hepatocellular Carcinoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1